KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference

KPI-150 Kv1.3 inhibitor from dalazatide family under development for atopic dermatitis with promising new data

SEATTLE, WA May 12, 2016 – KPI Therapeutics, a clinical-stage biotechnology company, today presented plaque psoriasis data from its dalazatide Phase 1B clinical trial at the 75th Society for Investigative Dermatology Conference in Scottsdale, AZ. KPI’s Dr. Chelsea Olsen presented the data on dalazatide, a first-in-class peptide inhibitor of the Kv1.3 potassium channel implicated in many autoimmune diseases.
Using novel compounds from the dalazatide family, KPI is also developing a topical biologic Kv1.3 inhibitor, KPI-150, for atopic dermatitis. This agent targets the immune cells which cause autoimmune diseases.

“The results from our Phase 1B clinical trial in psoriasis validated the mechanism of action of dalazatide in a prototypical T cell mediated autoimmune disease and demonstrated its potential as a first-in-class Kv1.3 inhibitor. With the encouraging proof-of-concept efficacy data we saw in this trial there is potential for breakthrough treatments in a number of other autoimmune diseases,” said Dr. Olsen. “Recent data shows that there is even higher Kv1.3 expression in atopic dermatitis lesional skin than in psoriasis lesional skin, making atopic dermatitis a promising target for treatment with KPI-150.

“The psoriasis trial also demonstrated that not only is dalazatide safe and well tolerated, but that it can improve skin lesions in individuals with plaque psoriasis by specifically inhibiting effector memory T cell activation and decreasing the levels of inflammatory cytokines,” Dr. Olsen added.

Atopic dermatitis is a chronic inflammatory autoimmune disease which causes itching, scratching, scaling, insomnia and loss of skin surface. Current cases of atopic dermatitis in the US exceed 15 million, with over half of these cases in people less than 20 years old.

**POSTER**

**About dalazatide**

Dalazatide completed a Phase 1B clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel - a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma. Dalazatide is being developed jointly with Kineta Inc.
About KPI-150

KPI-150 is a compound from the dalazatide family that also blocks the Kv 1.3 channel. KPI is developing this agent as a topical cream for atopic dermatitis, psoriasis and other dermatological complications associated with inflammatory diseases. Chronically activated TEM cells in atopic dermatitis are the target of KPI-150. A robust safety database exists for KPI compounds.

ABOUT KPITHERAPEUTICS

KPI Therapeutics is a clinical stage biotechnology company which develops first in class therapies for unmet medical needs in autoimmunity and chronic pain. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics which includes Seattle Children’s Research Institute. With its lead development partner Kineta, Inc, KPI is advancing the development of dalazatide (systemic autoimmune diseases including lupus) and CSP conopeptides (chronic pain). For more information about KPI please visit our website: kpitherapeutics.com

ABOUT KINETA

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.kinetabio.com
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI's plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Dan Eramian, Senior Vice President Communications and Investor Relations, KPI Therapeutics, Inc., deramian@kpitherapeutics.com 206-518-5566